Treatment with CNCs mitigates the severity of NASH by reducing expression of genes associated with the uptake of free fatty acids (CD36), liver inflammation (HMGB–1) and fibrosis (α–SMA). The gene discussed is CD36; the disease is metabolic dysfunction-associated steatohepatitis.